Literature DB >> 33878503

Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.

Corinne E Metzger1, Elizabeth A Swallow1, Alexander J Stacy1, Matthew R Allen2.   

Abstract

Chronic kidney disease (CKD) leads to loss of cortical bone through cortical thinning and the development of cortical porosity. The goal of this current study was to assess cortical bone alterations to adenine-induced chronic kidney disease (CKD) in two strains of mice with known genetic differences in cortical thickness. We hypothesized that C3H mice with thicker cortices and baseline levels of intracortical remodeling would have greater cortical porosity in response to adenine-induced CKD compared to B6 animals.
METHODS: Female C57BL/6 J (B6) and C3H/Hej (C3H) at 16-weeks of age were given a diet with 0.2% adenine to induce CKD for 6 weeks followed by a control diet for 4 weeks. Age- and strain-matched controls were fed the control diet without adenine for the 10-week period (n = 8 per group per strain).
RESULTS: Both strains of adenine-fed mice had elevated blood urea nitrogen, demonstrating compromised kidney function, compared to strain-matched controls, but only B6 adenine mice had statistically higher parathyroid hormone (PTH), greater cortical porosity, high bone turnover rate, a greater percentage of osteocytes positive for RANKL and IL-17, and lower osteocyte apoptosis compared to B6 controls. C3H mice had intracortical remodeling present in both control and adenine mice, while B6 mice had intracortical remodeling present only in adenine mice. Adenine mice of both strains had lower cortical thickness and a higher percentage of osteocytes positive for TNF-α compared to controls.
CONCLUSION: While both strains of mice had biochemical markers of kidney disease, only B6 mice developed a phenotype with significantly elevated PTH, high bone turnover, and cortical porosity development. This work, in a model of progressive CKD, further confirms the role of chronically elevated PTH in the development of cortical porosity and demonstrates adenine-induced increases in PTH contribute to intracortical remodeling in B6 mice. Adenine-induced changes that occurred in both strains of mice, notably lower cortical thickness and a higher percentage of osteocytes expressing TNF-α, indicate potential PTH-independent responses to CKD. Published by Elsevier Inc.

Entities:  

Keywords:  Chronic kidney disease; Cortical porosity; Parathyroid hormone

Mesh:

Substances:

Year:  2021        PMID: 33878503      PMCID: PMC8102422          DOI: 10.1016/j.bone.2021.115963

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.626


  48 in total

1.  Genetic background influences cortical bone response to ovariectomy.

Authors:  Chao Yang Li; Mitchell B Schaffler; Henock T Wolde-Semait; Christopher J Hernandez; Karl J Jepsen
Journal:  J Bone Miner Res       Date:  2005-08-22       Impact factor: 6.741

2.  TNF-α upregulates sclerostin expression in obese mice fed a high-fat diet.

Authors:  Kyunghwa Baek; Hyo Rin Hwang; Hyun-Jung Park; Arang Kwon; Abdul S Qadir; Seong-Hee Ko; Kyung Mi Woo; Hyun-Mo Ryoo; Gwan-Shik Kim; Jeong-Hwa Baek
Journal:  J Cell Physiol       Date:  2014-05       Impact factor: 6.384

3.  Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study.

Authors:  Anoop Shankar; Liping Sun; Barbara E K Klein; Kristine E Lee; Paul Muntner; F Javier Nieto; Michael Y Tsai; Karen J Cruickshanks; Carla R Schubert; Peter C Brazy; Josef Coresh; Ronald Klein
Journal:  Kidney Int       Date:  2011-08-24       Impact factor: 10.612

4.  Relationship between moderate to severe kidney disease and hip fracture in the United States.

Authors:  Thomas L Nickolas; Donald J McMahon; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

5.  Tail suspension induces bone loss in skeletally mature mice in the C57BL/6J strain but not in the C3H/HeJ strain.

Authors:  Daniel Amblard; Marie-Hélène Lafage-Proust; Andres Laib; Thierry Thomas; Peter Rüegsegger; Christian Alexandre; Laurence Vico
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

6.  Immunologic function and survival in hemodialysis patients.

Authors:  P L Kimmel; T M Phillips; S J Simmens; R A Peterson; K L Weihs; S Alleyne; I Cruz; J A Yanovski; J H Veis
Journal:  Kidney Int       Date:  1998-07       Impact factor: 10.612

Review 7.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.

Authors:  Steeve Kwan Tat; Marc Padrines; Sandrine Théoleyre; Dominique Heymann; Yannick Fortun
Journal:  Cytokine Growth Factor Rev       Date:  2004-02       Impact factor: 7.638

8.  IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice.

Authors:  Jau-Yi Li; Patrizia D'Amelio; Jerid Robinson; Lindsey D Walker; Chiara Vaccaro; Tao Luo; Abdul Malik Tyagi; Mingcan Yu; Michael Reott; Francesca Sassi; Ilaria Buondonno; Jonathan Adams; M Neale Weitzmann; Giovanni Carlo Isaia; Roberto Pacifici
Journal:  Cell Metab       Date:  2015-10-08       Impact factor: 27.287

9.  DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone.

Authors:  Corinne E Metzger; S Anand Narayanan; Jon P Elizondo; Anne Michal Carter; David C Zawieja; Harry A Hogan; Susan A Bloomfield
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

10.  Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models.

Authors:  Guaraciaba O Ferrari; Juliana C Ferreira; Raquel T Cavallari; Katia R Neves; Luciene M dos Reis; Wagner V Dominguez; Elizabeth C Oliveira; Fabiana G Graciolli; Jutta Passlick-Deetjen; Vanda Jorgetti; Rosa M A Moysés
Journal:  BMC Nephrol       Date:  2014-05-03       Impact factor: 2.388

View more
  4 in total

1.  Analysis of bone in adenine-induced chronic kidney disease model rats.

Authors:  Hikaru Saito; Naohisa Miyakoshi; Yuji Kasukawa; Koji Nozaka; Hiroyuki Tsuchie; Chiaki Sato; Kazunobu Abe; Ryo Shoji; Yoichi Shimada
Journal:  Osteoporos Sarcopenia       Date:  2021-11-20

2.  CKD Stages, Bone Metabolism Markers, and Cortical Porosity Index: Associations and Mediation Effects Analysis.

Authors:  Yan Xiong; Tongxiang He; Yanan Wang; Weiyin Vivian Liu; Shuang Hu; Yao Zhang; Donglin Wen; Bowen Hou; Yitong Li; Peisen Zhang; Jianyi Liu; Fan He; Xiaoming Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

3.  Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.

Authors:  Elizabeth A Swallow; Corinne E Metzger; Neal X Chen; Joseph M Wallace; Samantha P Tippen; Rachel Kohler; Sharon M Moe; Matthew R Allen
Journal:  Bone Rep       Date:  2022-02-07

4.  Cortical porosity occurs at varying degrees throughout the skeleton in rats with chronic kidney disease.

Authors:  Corinne E Metzger; Christopher L Newman; Samantha P Tippen; Natalie T Golemme; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone Rep       Date:  2022-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.